Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets

Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies. In this study, we performed whole exome and RNA-Seq analysis metastases to determine the nature and frequency of somatic mutations.]]>
Inclusion Criteria Patients must be greater than or equal to 16 years of age. Patients who have a premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis that requires surgery or biopsy as a part of the standard of care diagnosis, treatment and/or follow up. Patients must have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to biopsy or surgery. Patients must be planning to undergo surgery or biopsy as part of their treatment plan. Note: Patients will not be enrolled exclusively for the procurement of tissue samples. Patients who agree to undergo leukapheresis must meet the following criteria: Seronegative for HIV Seronegative for hepatitis B surface antigen and seronegative for antibody to hepatitis C CBC within normal limits ]]>